Cytokine Regulation in Autism

  • Vijendra K. Singh
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 7)


Autism is a biological disorder of unknown cause and etiology. The disorder impacts the functioning of the central nervous system (CNS), manifesting devastating psychiatric as well as neurological problems in the affected person. Autism is commonly described as a neurodevelopmental disorder, which implies that the structure and function of the developing brain is impaired. Today, autism is known to affect more than one-half million American people, by and large children but a significant number of adults also. The diagnosis is made during early childhood before the age of 34 months but the affliction continues well into the adulthood, becoming a life-long disability.


Myelin Basic Protein Myelin Sheath Normal Child Measle Virus Autistic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rimland, B. Huge increase of autism incidence reported in California; autism cluster investigated in Brick, New Jersey. Autism Research Review International 1999; 3:1.Google Scholar
  2. 2.
    Singh, V.K. Immunotherapy for brain disease and mental illnesses. Progr. Drug Res. 1997; 48:129–146.Google Scholar
  3. 3.
    Trottier, G., Srivastava, L. and Walker, C.D. Etiology and infantile autism: a review of recent advances in genetic and neurobiological research. J. Psychiat. Neurosci. 1999; 24:95–96.Google Scholar
  4. 4.
    Singh, V.K., Warren, R.P., Odell, J.D., et al. Antibodies to myelin basic protein in children with autistic disorder. Brain Beha. Immun. 1993; 7:97–103.CrossRefGoogle Scholar
  5. 5.
    Singh, V.K., Neuro-immunopathogenesis in autism. In New Foundation of Biology, Istvan, Berczi, Reginald, M., Gorczynski, R.M, ed. The Netherlands, Elsevier B.V. Publishing, 2001; 1:443–454.Google Scholar
  6. 6.
    Ermann, J., Fathman, C.G. Autoimmune diseases: genes, bugs and failed regulation. Nature Immunol. 2001; 2:759–761.CrossRefGoogle Scholar
  7. 7.
    Chess, S., Fernandez, P. and Korn, S. Behavioral consequences of congenital rubella. J. Pediatrics 1978; 93:699–703.CrossRefGoogle Scholar
  8. 8.
    Stubbs, E.G., Ash, E., Williams, P.S. Autism and congenital cytomegalovirus. J. Aut. Dev. Disord. 1984; 14:183–89.CrossRefGoogle Scholar
  9. 9.
    Ivarsson, S.A., Bjerre, I., Vegfors, P., et al. Autism as one of several disabilities in two children with congenital cytomegalovirus infection. Neuropediatrics 1989; 21:102–103.CrossRefGoogle Scholar
  10. 10.
    Warren, R.P., Singh, V.K., Cole, P., et al. Increased frequency of the null allele at the complement C4B locus in autism. Clin. Exptl. Immunol. 1991; 83:438–440.CrossRefGoogle Scholar
  11. 11.
    Warren, R.P., Singh, V.K., Averett, R.E., et al. Immunogenetic studies in autism and related disorders. Mol. Chem. Neuropathol. 1996; 28:77–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Warren, R.P., Odell, J.D., Warren, W.L., et al. Strong association of the third hypervariable region of HLA-DRbl with autism. J. Neuroimmunol. 1996; 67:97–102.PubMedCrossRefGoogle Scholar
  13. 13.
    Stubbs, E.G., Crawford, M.L., Burger, D.R., et al. Depressed lymphocyte responsiveness in autistic children. J. Aut. Childh. Schizophr. 1977; 7:49–55.CrossRefGoogle Scholar
  14. 14.
    Warren, R.P., Foster, A., Margaretten. N.C., et al. Immune abnormalities in patients with autism. J. Aut. Develop. Disord. 1986; 16:189–197.CrossRefGoogle Scholar
  15. 15.
    Warren, R.P., Foster, A. and Margaretten, N.C. Reduced natural killer cell activity in autism. J. Am. Acad. Child Adol. Psychol. 1987; 26:333–35.CrossRefGoogle Scholar
  16. 16.
    Singh, V.K., Fudenberg, H.H., Emerson, D., et al. Immunodiagnosis and immunotherapy in autistic children. Ann. N.Y. Acad. Sci. 1988; 540:602–604.PubMedCrossRefGoogle Scholar
  17. 17.
    Yonk, L.J., Warren, R.P., Burger, R.A., et al. CD4+ helper T cell depression in autism. Immunol. Lett. 1990; 25:341–346.PubMedCrossRefGoogle Scholar
  18. 18.
    Menage, P., Thibault, G., Barthelemy, C., et al. CD4+ CD45RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine-magnesium treatment. Brain Dysfunct. 1992; 5:326–333.Google Scholar
  19. 19.
    Gupta, S., Aggarwal, S. and Heads, C. Dysregulated immune system in children with autism: Beneficial effects of intravenous immune globulin on autistic characteristics. J Aut Develop Dis 1996; 26:439–452.CrossRefGoogle Scholar
  20. 20.
    Weizman, A., Weizman, R., Szekely, G.A., et al. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am. J. Psychiat. 1982; 139:1462–1465.PubMedGoogle Scholar
  21. 21.
    Money, J., Bobrow, N.A. and Clarke, F.C. Autism and autoimmune disease: a family study. J. Aut. Child Schizo. 1971; 1:146–160.CrossRefGoogle Scholar
  22. 22.
    Comi, A.M., Zimmerman, A.W., Frye, V.H., et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J. Child Neurol. 1999; 14:388–394.PubMedCrossRefGoogle Scholar
  23. 23.
    Singh, V.K., Warren, R.P., Averett, R., et al. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatric Neurology 1997; 16:88–90.CrossRefGoogle Scholar
  24. 24.
    Todd, R.D., Ciaranello, R.D. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc. Natl. Acad. Sci. USA 1985; 82:612–616.PubMedCrossRefGoogle Scholar
  25. 25.
    Singh, V.K, Singh, E.A. and Warren, R.P. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol. Psychiat. 1997; 41:753–755.PubMedCrossRefGoogle Scholar
  26. 26.
    Connelly, A.M., Chez, M.G., Pestronk, A., et al. Serum antibodies to brain in Landau-Kleffher variant, autism, and other neurological disorders. J. Pediatrics 1999; 134:607–613.CrossRefGoogle Scholar
  27. 27.
    Singh, V.K., Wu, E. and Tsui, B. Autoantibodies to neural proteins of caudate nucleus in autism. Proceedings of the International Meeting for Autism Research; San Diego, California, November 9–10, 2001Google Scholar
  28. 28.
    Plioplys, A.V., Greaves, A., Kazemi, K., et al. Lymphocyte function in autism and Rett syndrome. Neuropsychobiology 1994; 29:12–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Singh, V.K., Warren, R.P., Odell, J.D., et al. Changes of soluble interleukin-2, interleukin-2-receptor, T8 antigen, and interleukin-1 in the serum of autistic children, Clin. Immunol. Immunopath. 1991; 61:448–455.CrossRefGoogle Scholar
  30. 30.
    Singh, V.K. Plasma increase of interleukin-12 and interferon-γ: pathological significance in autism. J. Neuroimmunol. 1996; 66:143–145.PubMedCrossRefGoogle Scholar
  31. 31.
    Fudenberg, H.H. Dialyzable lymphocyte extract (DlyE) in infantile onset autism: A pilot study. Biotherapy 1996; 9:143–147.PubMedCrossRefGoogle Scholar
  32. 32.
    Singh, V.K., Lin, S.Y. and Yang, V.C. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin. Immunol. Immunopathol. 1998; 89:105–108.PubMedCrossRefGoogle Scholar
  33. 33.
    Singh, V.K. Immunological link between measles-mumps-rubella and autoimmune autism. Proceedings of the 11th International Congress for Immunology (ICI); 2001; A9; Stockholm, Sweden.Google Scholar
  34. 34.
    Madhur G. Indian scientists warn of “mutant measles” virus. Brit. Med. J. 2001; 322:693.Google Scholar
  35. 35.
    Singh, V.K. and Nelson, C. Abnormal measles serology and autoimmunity in autistic children. J. Allergy Clin. Immunol. (Supplement), 2002; 109: Abs. # 702.Google Scholar
  36. 36.
    Pabst, H.F., Spady, D.W., Carson, MM, et al. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 1997; 15:10–14.PubMedCrossRefGoogle Scholar
  37. 37.
    McClelland, R.J., Eyre, D.G., Watson, D., et al. Central conduction time in childhood autism. Brit. J. Psychiat. 1992; 160:659–663.PubMedCrossRefGoogle Scholar
  38. 38.
    Nevsimalova, S., Taubaerova, A., Doutlik, S., et al. A role of autoimmunity in the etiopathogenesis of Landau-Kleffner syndrome? Brain Dev. 1992; 14:342–350.PubMedCrossRefGoogle Scholar
  39. 39.
    Musiek, F.E., Gollegly, K.M. and Baran, J.A. Myelination of the corpus callosum and autditory processing problems in children: theoretical and clinical correlates. Seminar Hearing 1989; 5:231–241.CrossRefGoogle Scholar
  40. 40.
    Gupta, S., Rimland, B. and Shilling, P.D. Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J. Child Neurol. 1996; 11:501–504.PubMedCrossRefGoogle Scholar
  41. 41.
    Jyonouchi, H., Sun, S. and Le, H. Innate and adaptive immune responses in children with regression autism: evaluation of the effects of environmental factors including vaccination. J. Allergy Clin. Immunol. (Supplment) 2001; 107:Part 2, Abstract #897.Google Scholar
  42. 42.
    Hu, Y. Altered T cell-mediated immunity and infectious factors in autism. Doctor of Philosophy dissertation, Utah State University, Logan, Utah, 2000.Google Scholar
  43. 43.
    Liblau, R.S., Singer, S.M. and McDevitt, H.O. Thl and Th2 CD4+ cells in the pathogenesis of organ-specific diseases. Immunol Today 1995; 16:34–38.PubMedCrossRefGoogle Scholar
  44. 44.
    Singh, V.K., Mehrotra, S. and Agarwal, S.S. The paradigm of Thl and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol. Res. 1999; 20:147–161.PubMedCrossRefGoogle Scholar
  45. 45.
    Gupta, S., Aggarwal, S., Rashanravan, B., et al. Thl- and Th2-like cytokines in CD4+ and CD8+ cells in autism. J. Neuroimmunol. 1998; 85:106–109.CrossRefGoogle Scholar
  46. 46.
    Furiano, R.I., Anthony, A., Day, R., et al. Colonic CD8 and γδ T-cell infiltration with epithelial damage in children with autism. J. Pediatrics 2001; 138:366–372.CrossRefGoogle Scholar
  47. 47.
    Mosmann, T.R. and Sad, S. The expanding universe of T cell subsets: Thl, Th2 and more. Immunol. Today 1996; 17:138–146.PubMedCrossRefGoogle Scholar
  48. 48.
    Romagnani, S. Human Th1 and Th2 subsets. Immunol. Today 1997; 18:256–257.CrossRefGoogle Scholar
  49. 49.
    Abbas, A.K., Murphy, K.M. and Sher, A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787–793.PubMedCrossRefGoogle Scholar
  50. 50.
    Trinchieri, G. Interleukin-12 and its role in the generation of THl cells. Immunol. Today 1993; 14:335–338.PubMedCrossRefGoogle Scholar
  51. 51.
    McNight, A.J., Zimmer, G.J., Fogelman, I., et al. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J. Immunol. 1994; 152:2172–2179.Google Scholar
  52. 52.
    Das, G., Sheridan, S. and Janeway Jr, C.A. The source of early IFN-γ that plays a role in Th1 priming. J. Immunol. 2001; 167:2004–2010.PubMedGoogle Scholar
  53. 53.
    Singh, V.K. and Leu, S.J.C. Enhancing effect of corticotropin-releasing neurohormone on production of interleukin-1 and interleukin-2. Neurosci. Lett. 1990; 120:151–154.PubMedCrossRefGoogle Scholar
  54. 54.
    Leu, S.C. and Singh, V.K., Stimulation of interleukin-6 production by corticotropin-releasing factor. Cell. Immunol. 1992; 143:220–227.PubMedCrossRefGoogle Scholar
  55. 55.
    Hogan, M.M. and Vogel, S.N., Measurement of tumor necrosis factor a and β. Current Protocols in Immunology 1991; Unit 6.10.1–6.10.5.Google Scholar
  56. 56.
    Ichikawa, M., Koh, C.S., Inoue, A., et al. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induce with myelin oligodendrocyte glycoprotein peptide. J. Neuroimmunol. 2000; 102:56–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Vijendra K. Singh
    • 1
  1. 1.Department of Biology & Biotechnology CenterUtah State UniversityLoganUSA

Personalised recommendations